Search Result

Results for "

GH3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Collagen (1) COX (1) Cytochrome P450 (1) Deubiquitinase (1) FOXO (1) JNK (1) NF-κB (1) PGC-1α (1) Phospholipase (1) Potassium Channel (7) Reference Standards (1) Sirtuin (1) Somatostatin Receptor (3) TGF-β Receptor (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Endocrinology (4) Inflammation/Immunology (6) Metabolic Disease (1) Neurological Disease (4)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1462

Chlorzoxazone 3 Publications Verification	Cytochrome P450 Potassium Channel FOXO Amyloid-β	Neurological Disease Inflammation/Immunology
Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates *FOXO3* phosphorylation and Aβ. Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis ^[3] .

HY-101422

GAL-021 Maximum Cited Publications 6 Publications Verification	Potassium Channel	Inflammation/Immunology
GAL-021 is a potent BK_Ca-channel blocker. GAL-021 inhibits K_Ca1.1 in GH3 cells. GAL-021 is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 increases minute ventilation in rats and non-human primates .

HY-P1959A

Lanreotide acetate BIM 23014 acetate	Somatostatin Receptor	Endocrinology Cancer
Lanreotide (BIM 23014) acetate is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for the research of carcinoid syndrome .

HY-P1959

Lanreotide BIM 23014	Somatostatin Receptor	Endocrinology Cancer
Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome .

HY-114557

NSC 90469 3,5-Diiodo-L-thyronine	JNK NF-κB Sirtuin PGC-1α COX TGF-β Receptor Collagen	Metabolic Disease Inflammation/Immunology Endocrinology
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity ^[3] .

HY-149902

USP8-IN-3	Deubiquitinase	Cancer
USP8-IN-3 (Compd U51) is a deubiquitinase USP8 inhibitor with an IC₅₀ value of 4.0 μM. USP8-IN-3 also inhibits the proliferation of GH3 and H1957 cells with GI₅₀s of 37.03 μM and 6.01 μM, respectively .

HY-117931

NS004	Potassium Channel	Neurological Disease
NS004 is a potassium (BK) channel activator that increases Iberiotoxin (HY-P0190) or Tetraethylammonium (HY-B1793)-sensitive whole-cell efflux currents. NS004 also significantly increased the activity of individual GH3 cell BK channels and rat brain BK channels reorganized into planar lipid bilayers, causing an increase in channel mean open time, a decrease in intermittent time, and an increase in channel voltage/calcium sensitivity .

HY-108592

UCL 2077	Potassium Channel	Cardiovascular Disease Neurological Disease
UCL 2077 is a potassium channel and slow afterhyperpolarization (sAHP) inhibitor. UCL 2077 selectively blocks sAHP channels without affecting L-type Ca ²⁺ currents. UCL 2077 blocks KCNQ1- and KCNQ2-containing K ⁺ channels, decreases erg current amplitude, increases erg deactivation rate. UCL 2077 can be used for the research of hippocampus-dependent memory retrieval deficit and cardiac arrhythmias ^[3].

HY-101422A

GAL-021 sulfate	Potassium Channel	Inflammation/Immunology
GAL-021 sulfate is a potent BK_Ca-channel blocker. GAL-021 sulfate inhibits K_Ca1.1 in GH3 cells. GAL-021 sulfate is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 sulfate increases minute ventilation in rats and non-human primates .

HY-130070

QO-40	Potassium Channel	Neurological Disease
QO-40, a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative, is a *KCNQ2/KCNQ3* K ⁺ channels activator with an EC₅₀ of 6.94 μM. QO-40 stimulated Ca ²⁺-activated K ⁺ current (I_K(Ca)) with an EC₅₀ value of 2.3 μM in pituitary GH3 lactotrophs .

HY-101422R

GAL-021 (Standard)	Potassium Channel Reference Standards	Inflammation/Immunology
GAL-021 (Standard) is the analytical standard of GAL-021 (HY-101422). This product is intended for research and analytical applications. GAL-021 is a potent BKCa-channel blocker. GAL-021 inhibits KCa1.1 in GH3 cells. GAL-021 is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 increases minute ventilation in rats and non-human primates .

HY-165327

AGN-190383	Phospholipase	Inflammation/Immunology
AGN-190383 is a bee venom phospholipase A2 inhibitor. AGN 190383 inhibits both hormone-operated and depolarization-dependent calcium mobilization as well as fMLP stimulated increases in free cytosolic calcium. AGN-190383 has anti-inflammatory activity .

HY-P1959B

Lanreotide diTFA BIM 23014 diTFA	Somatostatin Receptor	Endocrinology Cancer
Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome .

Lanreotide acetate BIM 23014 acetate	Somatostatin Receptor	Endocrinology Cancer
Lanreotide (BIM 23014) acetate is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for the research of carcinoid syndrome .

Lanreotide BIM 23014	Somatostatin Receptor	Endocrinology Cancer
Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome .

Lanreotide diTFA BIM 23014 diTFA	Somatostatin Receptor	Endocrinology Cancer
Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-114557

NSC 90469 3,5-Diiodo-L-thyronine	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Phenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	JNK NF-κB Sirtuin PGC-1α COX TGF-β Receptor Collagen
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity ^[3] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

GH3

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products